The effect of halogenation on blood-brain barrier permeability of a novel peptide drug

被引:114
|
作者
Gentry, CL [1 ]
Egleton, RD [1 ]
Gillespie, T [1 ]
Abbruscato, TJ [1 ]
Bechowski, HB [1 ]
Hruby, VJ [1 ]
Davis, TP [1 ]
机构
[1] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA
关键词
blood-brain barrier; brain endothelial cells; permeability coefficient; halogens; peptide drug; lipophilicity; delta opioid receptor;
D O I
10.1016/S0196-9781(99)00127-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and remain metabolically stable to produce the desired effect. To improve central nervous system entry of the opioid analgesic [o-Pen(2), r-Pen(5), Phe(6)] Enkephalin (DPLPE-Phe), our research group synthesized analogs that had chloro, bromo, fluoro, and iodo halogens on the para positions of the phenylalanine-4 residue. This study reports on investigation of the effect of halogenation on stability, lipophilicity, and in vitro blood-brain barrier permeability of a novel enkephalin analog DPLPE-Phe. The stability of each halogenated DPLPE-Phe analog as well as the amidated and nonamidated parent peptide was tested in plasma and brain. All peptides tested had a half-time disappearance >300 min except for DPLPE-Phe-NH2, which was found to have a half-life of 30 min in plasma. Octanol/saline distribution studies indicated addition of halogens to DPLPE-Phe-OH significantly increased lipophilicity except for p-[F-Phe(4)]DPLPE-Phe-OH. p-[Cl-Phe(4)]DPLPE-Phe-OH exhibited the most pronounced increase in lipophilicity. Para-bromo and para-chloro halogen additions significantly enhanced in vitro blood-brain barrier permeability, providing evidence for improved delivery to the central nervous system. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1229 / 1238
页数:10
相关论文
共 50 条
  • [1] Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability
    Witt, KA
    Gillespie, TJ
    Huber, JD
    Egleton, RD
    Davis, TP
    PEPTIDES, 2001, 22 (12) : 2329 - 2343
  • [2] PERMEABILITY OF THE BLOOD-BRAIN BARRIER
    BATES, IP
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1985, 6 (11) : 447 - 450
  • [3] Peptide Shuttles for Blood-Brain Barrier Drug Delivery
    Sanchez-Navarro, Macarena
    Giralt, Ernest
    PHARMACEUTICS, 2022, 14 (09)
  • [4] Towards Novel Biomimetic In Vitro Models of the Blood-Brain Barrier for Drug Permeability Evaluation
    Marmol, Ines
    Abizanda-Campo, Sara
    Ayuso, Jose M.
    Ochoa, Ignacio
    Olivan, Sara
    BIOENGINEERING-BASEL, 2023, 10 (05):
  • [5] Drug-protein binding and blood-brain barrier permeability
    Tanaka, H
    Mizojiri, K
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 288 (03): : 912 - 918
  • [6] Methods to assess drug permeability across the blood-brain barrier
    Nicolazzo, JA
    Charman, SA
    Charman, WN
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (03) : 281 - 293
  • [7] Effect of LPS on the permeability of the blood-brain barrier to insulin
    Xaio, HP
    Banks, WA
    Niehoff, ML
    Morley, JE
    BRAIN RESEARCH, 2001, 896 (1-2) : 36 - 42
  • [8] EFFECT OF NICKEL CHLORIDE ON PERMEABILITY OF BLOOD-BRAIN BARRIER
    VARKONYI, T
    JOO, F
    EXPERIENTIA, 1968, 24 (05): : 452 - &
  • [9] Effect of procyanidolic oligomers on the permeability of the blood-brain barrier
    Robert, AM
    Tixier, JM
    Robert, L
    Legeais, JM
    Renard, G
    PATHOLOGIE BIOLOGIE, 2001, 49 (04): : 298 - 304
  • [10] Permeability of the Blood-Brain Barrier to a Rhenacarborane
    Hawkins, Patrick M.
    Jelliss, Paul A.
    Nonaka, Naoko
    Shi, Xiaoming
    Banks, William A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 329 (02): : 608 - 614